Dr. Ying Wang 王颖
Chief Physician
Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for malignant tumors, including nasopharyngeal cancer, lung cancer, and pediatric tumors. Techniques include 3D conformal, intensity-modulated, volumetric modulated arc, and helical tomotherapy.
Dr. Wang holds a medical doctorate from Chongqing Medical University and completed postdoctoral research at Paris Diderot University. Training includes radiation oncology studies in Montpellier, France (DU diploma), and intensity-modulated radiation therapy at Shandong Cancer Hospital. With over 10 years of clinical experience, Dr. Wang specializes in radiation therapy for lung, nasopharyngeal, breast, and abdominal tumors, with specific research focus on intracranial tumors and non-small cell lung cancer.
Professional roles
- Member, Chinese Medical Association
- National Youth Committee Member, Radiation Oncology Branch, Chinese Medical Association
- Organizing Committee Member, National Nasopharyngeal Cancer Professional Committee
- Member, Chongqing Radiation Oncology Society
Name order: in Chinese the family name comes first (Wang Ying). Papers usually list the name as Ying Wang or Wang Y.
Selected publications
116 papers on PubMed matched by name and affiliation; 25 as first or senior author since 2016. Most recent first- or senior-author papers:
- Precis Radiat Oncol, 2026 (senior author): Integrated multi-omics analysis of post-translational modifications in head and neck squamous cell carcinoma: elucidating x-ray and carbon ion irradiation effects. PubMed 42807604
- Precis Radiat Oncol, 2026 (senior author): Exosomal hnRNPA1-delivered miR-27a-3p inhibits the radiation-induced bystander effect in cervical cancer. PubMed 42609938
- Cancer Imaging, 2026 (senior author): Recursive partitioning analysis model based on (18)F-FDG PET/CT metabolic parameters for recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 inhibitors and chemotherapy. PubMed 42972443
- J Asthma, 2026 (senior author): Elevated IL1RL1 expression is correlated with the persistence of childhood allergies. PubMed 42427164
- J Exp Clin Cancer Res, 2026 (senior author): hnRNPA1-SF3B3 interaction drives radioresistance in oral squamous cell carcinoma by modulating MARF1 alternative splicing isoforms. PubMed 41864998
- Front Oncol, 2025 (senior author): Correction: Monocyte count combined with GTVnx is an independent prognostic factor in non-metastatic nasopharyngeal carcinoma receiving radiotherapy. PubMed 40909969
- Clin Respir J, 2025 (senior author): Comprehensive Analysis of Lung Cancer Metastasis: Sites, Rates, Survival, and Risk Factors-A Systematic Review and Meta-Analysis. PubMed 40650339
- Front Oncol, 2025 (senior author): Monocyte count combined with GTVnx is an independent prognostic factor in non-metastatic nasopharyngeal carcinoma receiving radiotherapy. PubMed 40265015
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion